Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics Inc. (FHTX)
Company Research
Source: GlobeNewswire
New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer Preclinical characterization of FHT-171, a selective CBP degrader with promise in ER+ breast cancer Progress across Selective EP300 degrader in hematological malignancies and Selective ARID1B degrader in ARID1A-mutant tumors WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will have multiple oral and poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026, in San Diego, California. New preclinical data for Selective SMARCA2 inhibitor FHD-909 will be featured as part of an oral presentation and preclinical data for Selective CBP
Show less
Read more
Impact Snapshot
Event Time:
FHTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FHTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FHTX alerts
High impacting Foghorn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
FHTX
News
- Foghorn Therapeutics (FHTX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=FHTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "bMarketBeat
- Foghorn Therapeutics (FHTX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Foghorn Therapeutics (FHTX) had its "outperform" rating reaffirmed by Wedbush. They now have a $10.00 price target on the stock.MarketBeat
- Foghorn Therapeutics GAAP EPS of -$1.18 misses by $0.08, revenue of $30.91M misses by $0.31M [Seeking Alpha]Seeking Alpha
- Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook [Yahoo! Finance]Yahoo! Finance
FHTX
Earnings
- 3/11/26 - Miss
FHTX
Sec Filings
- 4/13/26 - Form 4
- 3/26/26 - Form S-8
- 3/11/26 - Form 10-K
- FHTX's page on the SEC website